Portable ambulatory medical devices have proved useful for treating patients with medical conditions that require continuous monitoring and/or treatment. One example of such a portable ambulatory medical device is a device that involves the delivery of fluids. There are many applications in academic, industrial, and medical fields, as well as others, that involve devices capable of accurately and controllably delivering fluids, including liquids and gases, that have a beneficial effect when administered in known and controlled quantities. This is particularly true in the medical field, where treatments for many of patients include the administration of a known amount of a substance at predetermined intervals. For example, the treatment of diabetes involves just such a regimented dosage of medicaments such as insulin. In addition, diabetes is one of a few medical indications wherein patients routinely administer the medicament to themselves by a subcutaneous modality, such as a hypodermic syringe injection or by an ambulatory infusion pump. As such, providing a patient with the means to safely, reliably, and comfortably administer required doses of medication such as, e.g., insulin, may be particularly important in order to facilitate patient compliance and accurate treatment of the condition.
Ambulatory insulin infusion pumps have been developed for the administration of insulin for those diagnosed with both type I and type II diabetes. Ambulatory insulin pumps are medical infusion devices used for the administration of insulin in the treatment of diabetes, and offer an alternative to multiple daily injections of insulin by an insulin syringe or an insulin pen. They also allow for continuous insulin therapy. In addition, some ambulatory insulin infusion devices can include data collection and storage mechanisms, which allow a diabetic person and/or a doctor to easily monitor and adjust insulin intake. The infusion device may be powered by a rechargeable battery that requires periodic recharging.
Some ambulatory medical devices include a touchscreen on which symbols may be displayed and from which inputs may be received for operation of the device. Other input mechanisms involve keyboards or hardware switches. In general, a series of display screens or windows are shown on a device display or on the device touchscreen, showing alphanumeric text and symbols, and providing menu screens through which the user can control operation of the device. User interaction, such as by touching the alphanumeric text and symbols, provides user input and facilitates navigation through the menu screens and selection of the device functions.
The phenomenon of unintended, inadvertent activation of portable devices is not an uncommon occurrence. Telephone calls accidentally placed via a mobile telephone through inadvertent activation have become a fact of modern life. Such accidental calls can be annoying and troublesome for a mobile telephone. In the case of a portable ambulatory medical device, such accidental activation can have serious consequences. In fact, in the case of portable ambulatory medical devices, any changes at all that are unintended or inadvertent may be problematic and even dangerous. For example, an untimely delivery of insulin, or delivery of an unexpectedly changed amount of insulin, or the absence of an expected dose, can have extremely deleterious results, and may even be dangerous to the user. User safety would be improved with a reduction in the likelihood of an accidental or unintended activation or deactivation of a portable ambulatory medical device.
Disclosed herein are portable ambulatory medical devices and methods of operation that provide a reduced likelihood of inadvertent change in device operation. A device includes an active mode in which the device receives a user input at an input interface of the device and provides the received user input to a processor of the device. The active mode can be terminated and the device operated in a safe mode, in which the received user input is not provided to the processor and/or one or more device function is disabled, in response to determining that the received user input was received in an out of bounds region of the input interface. The safe mode is terminated in response to receiving a predetermined user input comprising an activation input. In some embodiments, the activation input can comprise selection of a wake display button or icon of the user interface, or may comprise a predetermined sequence of selected buttons or icons of the user interface.
In one embodiment, the activation input may be modified to require a timed pattern to wake the touchscreen. The pattern would require two or more presses that would be delivered in specified time windows, and if presses where detected outside of these windows, the sequence would be aborted.
In some embodiments, the portable device may include a user interface with control features such as buttons, switches or icons to control pumping and other functions, and the portable device may include a touchscreen on which are displayed alphanumeric text, symbols, menu screens, data, alerts, and other information. The device may show one or more screens or windows on the touchscreen through which device control inputs are received. For each device screen display, one or more regions of the display, and/or one or more buttons or switches, will be considered out of bounds for any intended control input. During an active mode of the device, when control inputs are received, any user interaction with an out of bounds region can cause the active mode to be suspended and the device will be in a safe mode of operation in which at least one of the device components is not operated. The device will remain in the safe mode until it receives an activation input before permitting continued active operation. The activation input may comprise a sequence of multiple inputs from the user via the touchscreen or a group of multiple inputs provided simultaneously, such as multiple simultaneous button presses. Failure to receive the activation input will result in the device remaining in the safe mode. The activation input may require the user to comply with activation sequence parameters as to both multiple symbol interactions and time between the multiple interactions. Requiring the predetermined activation sequence before resuming normal operation reduces the likelihood of accidental or unintended activation of the portable ambulatory medical device and improves user safety.
Other features and advantages of the present invention should be apparent from the following description of preferred embodiments that illustrate, by way of example, the principles of the invention.
The drawings illustrate embodiments of the technology and are not limiting. For clarity and ease of illustration, the drawings may not be made to scale and, in some instances, various aspects may be shown exaggerated or enlarged to facilitate an understanding of particular embodiments.
Disclosed herein are embodiments directed to a portable medical device having an interactive display screen, such as a touch screen, for control by the user, and having a connecting tube with an infusion port for administering medication to a patient.
The portable device 100 may be coupled to a patient 314 via an infusion port 116 and a connecting tube or cannula 118. The connecting lube is coupled to the portable device 100 at a fluid dispensing port 120. The portable device may include control features, such as buttons or switches 121 to receive user input and control pumping and other features, and may include a display screen 122 on which are displayed messages and alerts. The display 122 may comprise, for example, a touchscreen on which user inputs may be received. A housing 124 of the portable device encloses internal components, such as fluid reservoirs, electrical components, battery, and the like. The portable device 100 illustrated in
The portable device 100 can be coupled to a host power source such as a desktop or laptop computer, through a cable connected to the connector port 110. The cable may comprise, for example, a coupling through which both data and electrical energy are received at the portable device 100. Examples of such combined power and data cables include a Universal Serial Bus (USB) connection, an IEEE 1499 (FireWire) connection, a “THUNDERBOLT” connection (from Apple, Inc. of Cupertino, Calif., USA), PCI Express, eSATA and Ethernet.
The device 100 may also include a capability to operatively couple to one or more other devices via a wired or wireless (e.g., infrared, electronic, optical, etc.) link, locally or via a network, such as, e.g., a portable or non-portable medical device, a control unit, external monitor or display, a personal laptop, tablet or mainframe computer, or mobile communication device such as a smartphone or personal digital assistant (PDA). Such other devices may control or be controlled by device 100 and/or may otherwise communicate for the transfer of data including device parameters between or among device 100 and other device(s) for analysis of data (e.g., user data for physician review, device diagnostic data for troubleshooting or repair), programming, or other uses.
The portable device 100 may include control features such as buttons, panels, screens, and/or switches to control the device, or any combination of such control features. For example, the portable device 100 illustrated in
Device parameters provided by the portable infusion device may be presented on the display screen 122 as any number of objects, including one or more numeric and/or alphanumeric values, a range, a value or range that is presented in the form of a drop-down menu, a toggle that can be adjusted by the user, a graphical representation (e.g., icon) or an animated graphic. For instance, in certain embodiments, the value is a range of values that are presented on a screen of the display as a toggle, wherein the toggle may be adjusted upwards or downwards by the user swiping a finger over the screen to select the appropriate value range, e.g. appropriate range of amounts of medicament such as insulin to be delivered and/or the appropriate rate, time, or interval of medicament delivery. In certain instances, the values presented in the range may be adjusted by the processor (illustrated in
The type of touch screen 122 may vary as desired to be useful for a particular application, such as LCD displays, LED displays, plasma displays, organic LED (OLED) displays, and the like. The touchscreen 122 may be implemented with a capacitance screen, a resistive screen, or other such display/input technology. The portable device 100 may additionally include a keyboard or other input device known in the art for data entry, which may be separate from the display.
A control processor 218 is connected to the system bus 212 and receives the data communications from the connector data element 208 for processing. The control processor controls operation of the various elements of the portable device 100 that are connected to the system bus. The control processor operates according to mode instructions that may be stored in device memory 220.
The portable device 100 operates under control of the processor 218 so as to include at least two modes of operation, comprising an active mode and a safe mode. The active mode is an operating mode in which multiple device components are operated. The safe mode is an operating mode in which at least one device component is deactivated and is not operated. For example, in the active mode, the touchscreen display 122 and the pump 226 may be operated, whereas, in the safe mode, the pump may be deactivated and not operated.
Returning to the flow diagram of
While in the safe mode of operation, the processor waits for an input comprising an activation input. If an activation input is received, an affirmative outcome at box 310, then the process terminates the safe mode of operation at step 312. Typically, the processor will return to the active mode of operation, but other modes may be initiated, as desired. For example, a power saving mode might be preferred. If no activation input is received, a negative outcome at box 310, then the processor maintains the device in the safe mode.
The activation input may comprise selection of a wake display button or icon of the user interface. Alternatively, the activation input may comprise predetermined sequence of selected buttons or icons of the user interface. For example, the sequence may comprise discrete selection of predetermined buttons on the touchscreen display. In another alternative, the predetermined sequence may comprise a sequence of predetermined button selections separated by predetermined amounts of time. For example, the predetermined sequence may involve button selections that are separated in time by no more than an activation time value. The activation time value may have a value of, for example, no more than two seconds. If the time elapsed between any two display button selections is greater than two seconds, then the processor will consider the inputs to be random or accidental, and the processor will remain in the safe mode. In a further embodiment, the activation input can comprise a user swiping a touchscreen in a predetermined pattern or shape.
In some embodiments, the safe mode can also be entered at the end of one or more predetermined sequences of user interaction with the pump, such as a sequence after which a user is likely to be finished interacting with a pump for a period of time. For example, after a user programs a bolus and executes a deliver command, the pump can automatically enter a safe mode in which the screen is locked. This would prevent the user from inadvertently cancelling or modifying the bolus or otherwise interacting with the device in an unintended fashion during the bolus delivery while, for example, placing the pump back against the user's body. Pump operation can therefore subsequently be modified during delivery of the bolus only by unlocking the screen as described above. In one embodiment, the pump can remain locked after the bolus is delivered and until the screen is unlocked.
Although the aforementioned description specifically describes a portable medical device for administering insulin to a patient, it should be understood that such a device is only one embodiment of the invention. The device can also include any portable device having a display and a processor. For example, the device can include a mobile computing device, such as a Smartphone. In one embodiment, such a mobile computing device can be used as a remote control to wirelessly control operations of medical devices as disclosed herein. Alternatively, medical devices as disclosed herein can be controlled remotely with a dedicated remote control specifically designed for use with the medical device.
The methods, systems, and devices discussed above are intended merely to be examples. Various embodiments may omit, substitute, or add various procedures or components as appropriate. For example, it should be appreciated that, in alternative embodiments, the methods may be performed in an order different from that described, and various steps may be added, omitted, or combined. Also, features described with respect to certain embodiments may be combined in various other embodiments. Different aspects and elements of the embodiments may be combined in a similar manner. Also, it should be emphasized that technology evolves and, thus, many of the elements are examples and should not be interpreted to limit the scope of the invention.
Specific details are given in this description to provide a thorough understanding of the embodiments. Nevertheless, it will be understood by one of ordinary skill in the art that the embodiments may be practiced without these specific details. For example, well-known circuits, processes, algorithms, structures, and techniques have been shown without unnecessary detail in order to avoid obscuring the embodiments. Further, the headings provided herein are intended merely to aid in the clarity of the descriptions of various embodiments, and should not be construed as limiting the scope of the invention or the functionality of any part of the invention. For example, certain methods or components may be implemented as part of other methods or components, even though they are described under different headings.
It is noted that embodiments may have been described as a process that is depicted as a flow diagram or block diagram. Although each diagram may describe the process as a sequential series of operations, many of the operations can be performed in parallel or concurrently. In addition, the order of the operations may be rearranged. A process may have additional steps not included in the figures. Each operation of a process is performed or executed by the processor of the device.
The description above has been provided in terms of presently preferred embodiments so that an understanding of the present invention can be conveyed. There are, however, many configurations and techniques for data management systems that were not specifically described herein, but with which the present invention is applicable. The present invention should therefore not be seen as limited to the particular embodiments described herein, but rather, it should be understood that the present invention has wide applicability with respect to data management generally. All modifications, variations, or equivalent arrangements and implementations that are within the scope of the attached claims should therefore be considered within the scope of the invention.
The present application claims the benefit of U.S. Provisional Application No. 61/656,997 filed Jun. 7, 2012, which is incorporated herein in its entirety by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4810243 | Howson | Mar 1989 | A |
| 5247434 | Peterson et al. | Sep 1993 | A |
| 5497772 | Schulman et al. | Mar 1996 | A |
| 5498421 | Grinstaff et al. | Mar 1996 | A |
| 5558638 | Evers et al. | Sep 1996 | A |
| 5639473 | Grinstaff et al. | Jun 1997 | A |
| 5660163 | Schulman et al. | Aug 1997 | A |
| 5681285 | Ford et al. | Oct 1997 | A |
| 5707212 | Matthews | Jan 1998 | A |
| 5728396 | Peery et al. | Mar 1998 | A |
| 5782805 | Meinzer et al. | Jul 1998 | A |
| 5935099 | Peterson et al. | Aug 1999 | A |
| 5964724 | Rivera et al. | Oct 1999 | A |
| 5985305 | Peery et al. | Nov 1999 | A |
| 5988851 | Gent | Nov 1999 | A |
| 6198383 | Sekura et al. | Mar 2001 | B1 |
| 6241704 | Peterson et al. | Jun 2001 | B1 |
| 6269340 | Ford et al. | Jul 2001 | B1 |
| 6395292 | Peery et al. | May 2002 | B2 |
| 6427088 | Bowman, IV et al. | Jul 2002 | B1 |
| 6475180 | Peterson et al. | Nov 2002 | B2 |
| 6511435 | Bluth et al. | Jan 2003 | B1 |
| 6551276 | Mann et al. | Apr 2003 | B1 |
| 6554798 | Mann et al. | Apr 2003 | B1 |
| 6562001 | Lebel et al. | May 2003 | B2 |
| 6564105 | Starkweather et al. | May 2003 | B2 |
| 6571128 | Lebel et al. | May 2003 | B2 |
| 6577899 | Lebel et al. | Jun 2003 | B2 |
| 6585644 | Lebel et al. | Jul 2003 | B2 |
| 6635014 | Starkweather et al. | Oct 2003 | B2 |
| 6635048 | Ullestad et al. | Oct 2003 | B1 |
| 6648821 | Lebel et al. | Nov 2003 | B2 |
| 6659948 | Lebel et al. | Dec 2003 | B2 |
| 6668196 | Villegas et al. | Dec 2003 | B1 |
| 6687546 | Lebel et al. | Feb 2004 | B2 |
| 6694191 | Starkweather et al. | Feb 2004 | B2 |
| 6733446 | Lebel et al. | May 2004 | B2 |
| 6738052 | Manke et al. | May 2004 | B1 |
| 6740075 | Lebel et al. | May 2004 | B2 |
| 6744350 | Blomquist | Jun 2004 | B2 |
| 6758810 | Lebel et al. | Jul 2004 | B2 |
| 6810290 | Lebel et al. | Oct 2004 | B2 |
| 6811533 | Lebel et al. | Nov 2004 | B2 |
| 6811534 | Bowman, IV et al. | Nov 2004 | B2 |
| 6813519 | Lebel et al. | Nov 2004 | B2 |
| 6852104 | Blomquist | Feb 2005 | B2 |
| 6872200 | Mann et al. | Mar 2005 | B2 |
| 6873268 | Lebel et al. | Mar 2005 | B2 |
| 6936029 | Mann et al. | Aug 2005 | B2 |
| 6950708 | Bowman, IV et al. | Sep 2005 | B2 |
| 6958705 | Lebel et al. | Oct 2005 | B2 |
| 6974437 | Lebel et al. | Dec 2005 | B2 |
| 6979326 | Mann et al. | Dec 2005 | B2 |
| 6997920 | Mann et al. | Feb 2006 | B2 |
| 7024245 | Lebel et al. | Apr 2006 | B2 |
| 7025743 | Mann et al. | Apr 2006 | B2 |
| 7090648 | Sackner et al. | Aug 2006 | B2 |
| 7109878 | Mann et al. | Sep 2006 | B2 |
| 7118676 | Mueth et al. | Oct 2006 | B2 |
| 7141425 | Dzekunov et al. | Nov 2006 | B2 |
| 7171274 | Starkweather et al. | Jan 2007 | B2 |
| 7201730 | Davidner et al. | Apr 2007 | B2 |
| 7204823 | Estes et al. | Apr 2007 | B2 |
| 7207964 | Davidner et al. | Apr 2007 | B2 |
| 7256771 | Novak et al. | Aug 2007 | B2 |
| 7264730 | Connell et al. | Sep 2007 | B2 |
| 7303680 | Connell et al. | Dec 2007 | B2 |
| 7318892 | Connell et al. | Jan 2008 | B2 |
| 7347819 | Lebel et al. | Mar 2008 | B2 |
| 7347836 | Peterson et al. | Mar 2008 | B2 |
| 7351340 | Connell et al. | Apr 2008 | B2 |
| 7369635 | Spital et al. | May 2008 | B2 |
| 7471994 | Ford et al. | Dec 2008 | B2 |
| 7515060 | Blomquist | Apr 2009 | B2 |
| 7591801 | Brauker et al. | Sep 2009 | B2 |
| 7651489 | Estes et al. | Jan 2010 | B2 |
| 7654976 | Peterson et al. | Feb 2010 | B2 |
| 7678071 | Lebel et al. | Mar 2010 | B2 |
| 7699767 | Mueth et al. | Apr 2010 | B2 |
| 7713574 | Brister et al. | May 2010 | B2 |
| 7774145 | Brauker et al. | Aug 2010 | B2 |
| 7778680 | Goode, Jr. et al. | Aug 2010 | B2 |
| 7797028 | Goode, Jr. et al. | Sep 2010 | B2 |
| 7815602 | Mann et al. | Oct 2010 | B2 |
| 7819843 | Mann et al. | Oct 2010 | B2 |
| 7831310 | Lebel et al. | Nov 2010 | B2 |
| 7837647 | Estes et al. | Nov 2010 | B2 |
| 7837651 | Bishop et al. | Nov 2010 | B2 |
| 7912674 | Killoren Clark et al. | Mar 2011 | B2 |
| 7914450 | Goode, Jr. et al. | Mar 2011 | B2 |
| 7925321 | Goode et al. | Apr 2011 | B2 |
| 7933639 | Goode et al. | Apr 2011 | B2 |
| 7938792 | Roger et al. | May 2011 | B2 |
| 7955261 | Goode et al. | Jun 2011 | B2 |
| 7957984 | Vallone | Jun 2011 | B1 |
| 7959569 | Goode et al. | Jun 2011 | B2 |
| 7972296 | Braig et al. | Jul 2011 | B2 |
| 7976492 | Brauker et al. | Jul 2011 | B2 |
| 7976778 | Drucker et al. | Jul 2011 | B2 |
| 7979104 | Kamath et al. | Jul 2011 | B2 |
| 7986986 | Goode et al. | Jul 2011 | B2 |
| 7988849 | Biewer et al. | Aug 2011 | B2 |
| 8012119 | Estes et al. | Sep 2011 | B2 |
| 8034019 | Nair et al. | Oct 2011 | B2 |
| 8052601 | Goode, Jr. et al. | Nov 2011 | B2 |
| 8094009 | Allen et al. | Jan 2012 | B2 |
| 8130095 | Allen et al. | Mar 2012 | B2 |
| 8206350 | Mann et al. | Jun 2012 | B2 |
| 8211364 | Drucker et al. | Jul 2012 | B2 |
| 8221359 | Kristensen et al. | Jul 2012 | B2 |
| 8236242 | Drucker et al. | Aug 2012 | B2 |
| 8250483 | Blomquist | Aug 2012 | B2 |
| 8257652 | Drucker et al. | Sep 2012 | B2 |
| 8257653 | Drucker et al. | Sep 2012 | B2 |
| 8290562 | Goode, Jr. et al. | Oct 2012 | B2 |
| 8332008 | Goode et al. | Dec 2012 | B2 |
| 8346399 | Blomquist | Jan 2013 | B2 |
| 8369919 | Kamath et al. | Feb 2013 | B2 |
| 8390244 | Wooley et al. | Mar 2013 | B2 |
| 8401194 | Nierzwick et al. | Mar 2013 | B2 |
| 8449524 | Braig et al. | May 2013 | B2 |
| 8451230 | Celentano et al. | May 2013 | B2 |
| 8460231 | Brauker et al. | Jun 2013 | B2 |
| 8579853 | Reggiardo et al. | Nov 2013 | B2 |
| 9238100 | Kruse et al. | Jan 2016 | B2 |
| 9335910 | Farnan et al. | May 2016 | B2 |
| 20010027791 | Wallace et al. | Oct 2001 | A1 |
| 20020029776 | Blomquist | Mar 2002 | A1 |
| 20020078393 | Parker | Jun 2002 | A1 |
| 20020183693 | Peterson et al. | Dec 2002 | A1 |
| 20030065308 | Lebel et al. | Apr 2003 | A1 |
| 20030163088 | Blomquist | Aug 2003 | A1 |
| 20030163223 | Blomquist | Aug 2003 | A1 |
| 20030163789 | Blomquist | Aug 2003 | A1 |
| 20030199378 | Saviano | Oct 2003 | A1 |
| 20030212364 | Mann et al. | Nov 2003 | A1 |
| 20040193090 | Lebel et al. | Sep 2004 | A1 |
| 20040227737 | Novak | Nov 2004 | A1 |
| 20050022274 | Campbell et al. | Jan 2005 | A1 |
| 20050143864 | Blomquist | Jun 2005 | A1 |
| 20050160084 | Barrett | Jul 2005 | A1 |
| 20050171513 | Mann et al. | Aug 2005 | A1 |
| 20060073891 | Holt | Apr 2006 | A1 |
| 20060173444 | Choy et al. | Aug 2006 | A1 |
| 20060229557 | Fathallah et al. | Oct 2006 | A1 |
| 20070093786 | Goldsmith et al. | Apr 2007 | A1 |
| 20070118405 | Campbell et al. | May 2007 | A1 |
| 20070287985 | Estes et al. | Dec 2007 | A1 |
| 20080033357 | Mann et al. | Feb 2008 | A1 |
| 20080065007 | Peterson et al. | Mar 2008 | A1 |
| 20080065016 | Peterson et al. | Mar 2008 | A1 |
| 20080119705 | Patel et al. | May 2008 | A1 |
| 20080122595 | Yamamichi et al. | May 2008 | A1 |
| 20080147004 | Mann et al. | Jun 2008 | A1 |
| 20080147050 | Mann et al. | Jun 2008 | A1 |
| 20080171967 | Blomquist et al. | Jul 2008 | A1 |
| 20080172026 | Blomquist | Jul 2008 | A1 |
| 20080172027 | Blomquist | Jul 2008 | A1 |
| 20080172028 | Blomquist | Jul 2008 | A1 |
| 20080172029 | Blomquist | Jul 2008 | A1 |
| 20080172030 | Blomquist | Jul 2008 | A1 |
| 20080172031 | Blomquist | Jul 2008 | A1 |
| 20090167717 | Wang et al. | Jul 2009 | A1 |
| 20090192724 | Brauker et al. | Jul 2009 | A1 |
| 20090227888 | Salmi et al. | Sep 2009 | A1 |
| 20090254037 | Bryant, Jr. et al. | Oct 2009 | A1 |
| 20090270833 | Debelser et al. | Oct 2009 | A1 |
| 20090289916 | Dai | Nov 2009 | A1 |
| 20100107103 | Wallaert et al. | Apr 2010 | A1 |
| 20100121169 | Petisce et al. | May 2010 | A1 |
| 20100145262 | Bengtsson et al. | Jun 2010 | A1 |
| 20100168543 | Kamath et al. | Jul 2010 | A1 |
| 20100179402 | Goode, Jr. et al. | Jul 2010 | A1 |
| 20100261987 | Kamath et al. | Oct 2010 | A1 |
| 20100292556 | Golden | Nov 2010 | A1 |
| 20100312082 | Batman et al. | Dec 2010 | A1 |
| 20110009813 | Rankers | Jan 2011 | A1 |
| 20110040247 | Mandro et al. | Feb 2011 | A1 |
| 20110047499 | Mandro et al. | Feb 2011 | A1 |
| 20110053121 | Heaton | Mar 2011 | A1 |
| 20110071465 | Wang et al. | Mar 2011 | A1 |
| 20110092894 | McGill et al. | Apr 2011 | A1 |
| 20110098637 | Hill | Apr 2011 | A1 |
| 20110098638 | Chawla et al. | Apr 2011 | A1 |
| 20110098674 | Vicente | Apr 2011 | A1 |
| 20110106318 | Ledford | May 2011 | A1 |
| 20110119087 | Drucker et al. | May 2011 | A1 |
| 20110125085 | McGill et al. | May 2011 | A1 |
| 20110125095 | Lebel et al. | May 2011 | A1 |
| 20110125530 | Drucker et al. | May 2011 | A1 |
| 20110133946 | Kopp et al. | Jun 2011 | A1 |
| 20110144586 | Michaud et al. | Jun 2011 | A1 |
| 20110152770 | Diperna et al. | Jun 2011 | A1 |
| 20110190614 | Brister et al. | Aug 2011 | A1 |
| 20110256024 | Cole et al. | Oct 2011 | A1 |
| 20110257895 | Brauker et al. | Oct 2011 | A1 |
| 20120030610 | DiPerna et al. | Feb 2012 | A1 |
| 20120041415 | Estes et al. | Feb 2012 | A1 |
| 20120095315 | Tenbarge et al. | Apr 2012 | A1 |
| 20120109100 | Estes et al. | May 2012 | A1 |
| 20120130204 | Basta et al. | May 2012 | A1 |
| 20120185267 | Kamen et al. | Jul 2012 | A1 |
| 20130172710 | Mears et al. | Jul 2013 | A1 |
| 20130191770 | Bartz et al. | Jul 2013 | A1 |
| 20130283196 | Farnan et al. | Oct 2013 | A1 |
| 20130298024 | Rhee et al. | Nov 2013 | A1 |
| 20130332874 | Rosinko et al. | Dec 2013 | A1 |
| 20140012511 | Mensinger et al. | Jan 2014 | A1 |
| 20140180711 | Kamen et al. | Jun 2014 | A1 |
| 20140276531 | Walsh | Sep 2014 | A1 |
| 20160121047 | Kruse et al. | May 2016 | A1 |
| 20160199571 | Rosinko et al. | Jul 2016 | A1 |
| 20160271325 | Farnan et al. | Sep 2016 | A1 |
| Number | Date | Country |
|---|---|---|
| 1769812 | Apr 2007 | EP |
| 2079011 | Jul 2009 | EP |
| WO 9524229 | Sep 1995 | WO |
| WO 0018449 | Apr 2000 | WO |
| WO03008014 | Jan 2003 | WO |
| WO 2011005633 | Jan 2011 | WO |
| Entry |
|---|
| International Preliminary Report on Patentability dated Dec. 9, 2014 for PCT Application No. PCT/US2013/044329 filed Jun. 5, 2013, 9 pages. |
| PCT Search Report dated Sep. 4, 2013 for PCT Application No. PCT/US2013/044329 filed Jun. 13, 2013, 13 pages. |
| Application and File History for U.S. Appl. No. 13/801,274, filed Mar. 13, 2013, inventor Farnan et al. |
| Application and File History for U.S. Appl. No. 15/149,559, filed May 9, 2016, inventor Farnan et al. |
| Search Report for EP Application No. 13781696.3 dated Nov. 25, 2015. |
| Search Report and Written Opinion dated Jul. 29, 2013 for PCT Application No. PCT/US2013/037616 filed Apr. 22, 2013, 10 pages. |
| Written Opinion dated Oct. 28, 2014 for PCT Application No. PCT/US2013/037616 filed Apr. 22, 2013, 6 pages. |
| Communication dated Jun. 6, 2017 for EP Application No. 13800236.5, 9 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20130332874 A1 | Dec 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61656997 | Jun 2012 | US |